u/yusuf_ramos

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

the escalation is where most of the reported trouble sits

How many cycles has the pattern held for?

phase 2 finds a dose, phase 3 measures the effect

Push back: you did not lose that money by being stupid. You lost it to a shop with nothing verifiable on file, which is a different thing.

somebody will read this at the point you were at, and it will help

no referral links, ever, and that rule is why the pricing threads work

Pen or vial? The step sizes available differ and it changes this answer.

Yes — 10mg being a genuine landing place for a lot of people is underrated. There is no medal for 15.

That is a general statement about gastric emptying, and the question was about a specific product.

Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.

Do you have the publication or the press release?

Agreed — the incretin effect is the load-bearing concept and everything downstream reads differently once you have it.

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

albumin binding is most of the half-life story

Which pharmacy, and what did they quote for the month rather than the first month?

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

zepbound and mounjaro are the same compound with different labels

the peripheral and central stories are not in competition

Yes — the consultation that asks nothing tells you what kind of service it is.

Week 54 was the first time the scale moved after a five-week stall. I changed nothing in that window.

switching from sema is not a dose conversion, there is no clean equivalence

read the endpoint before you read the headline

a press release is not a publication

Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.

stepping every four weeks is a ceiling on speed, not a schedule you must hit

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

Stopped at a low step because there was no reason to go further and no data to tell me what further would do.

Four pharmacies, four prices, same product, same month. The spread was larger than I expected and none of them were the headline offer.

Same. A press release is a claim about a result; the publication is the result.

How long was the randomised phase before any extension?

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

Right — trial participants get structured support.

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

Are you comparing against phase 3 numbers for something else? They are not comparable.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state.

Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.